Innovation

BioNTech's earnings for Q4 2024 showed a decline, with EPS at 1.08 euros, contrasting sharply with 1.90 euros from the previous year, yet exceeding market expectations of 0.407 euros. Full-year…

Oryzon Genomics' shares surged by 20% to €3.69, increasing market capitalization to over €200 million, reflecting significant investor interest. The Phase IIa REIMAGINE study results on Vafidemstat showed promising effectiveness…